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Background
Chronic purulent rhinosinusitis (CPR) is an inflammatory
disorder of the nose and paranasal sinuses of unknown
cause. Despite various available medical and surgical
treatment options still 5 to 10% of patients remain refrac-
tory. Immune deficiency is one of the underlying risk fac-
tors for CPR and previous studies demonstrated defects
in monocyte chemotaxis. Subsequent treatment with the
thymic hormone preparation thymostimulin led to in
vitro restoration of monocyte chemotaxis and significant
clinical improvement in patients. However, thymostimu-
lin became unavailable in recent years. In the present
study we evaluated the effects of the thymic peptide thy-
mosin a1 on monocytes from CPR patients as well as
aberrant gene expression profiles in these monocytes in
order to further elucidate the pathogenesis of CPR.
Method
Monocytes were isolated from 16 patients with CPR and
13 healthy volunteers. Monocyte polarization was
assessed using the Cianciolo and Snyderman monocyte
polarization assay and the effects of thymosin a1 on
monocyte polarization were evaluated. Furthermore, by
Affymetrix whole-genome gene expression profiling and
Q-PCR analysis we analyzed aberrant gene expression
profiles in monocytes from CPR patients.
Results
In 4 out of 16 CPR patients we found diminished mono-
cyte polarization (45%, sd 8%) when compared to healthy
volunteers (58%, sd 12,5%)(p=0.078). More interestingly,
in vitro treatment with thymosin a1 significantly restored
monocyte polarization in these patients (64% sd 10%,
p=0.029). In the “poor polarizing” monocytes we found
aberrant expression of genes involved in pathways of
inflammation, chemotaxis and cell migration.
Conclusion
Patients with CPR show diminished monocyte polarization
in vitro that could be restored by thymosin a1. Moreover,
these monocytes show an aberrant gene expression profile.
We hypothesize that thymosin a1 may be a promising
agent in treatment of refractory CPR patients. These
effects may be mediated through interference with
pathways involving the aberrantly expressed genes.
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